Access to cancer medicine in Iran

The Lancet Oncology

Volumn 14, Issue 3, 2013, Pages

  Golzari, Samad E J ^a   Ghabili, Kamyar ^b   Khanli, Hadi Mohammad ^c   Tizro, Parastou ^c   Rikhtegar, Reza ^b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER INCIDENCE; CANCER MORTALITY; DRUG MARKETING; HEALTH CARE ACCESS; INTERNATIONAL RELATIONS; IRAN; LETTER; PRIORITY JOURNAL;

HUMANS; IRAN; MEDICINE; NEOPLASMS; PATIENT ACCEPTANCE OF HEALTH CARE;

EID: 84875273460     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70036-6     Document Type: Letter

References (4)

1. Access to cancer medicine in low-resource settings. Lancet Oncol 2013, 14:1. The Lancet Oncology.
2. Cancer WHO, Regional Office for the Eastern MediterraneanRegional Office for the Eastern Mediterranean, (accessed Jan 23, 2013). http://www.emro.who.int/health-topics/cancer/.
3. Ramezanian F Annual recognition of 85 000 cancer patients (in Persian; accessed Jan 23, 2013). http://www.magiran.com/npview.asp?ID=2546830.
4. World Cancer Day Union for International Cancer Control, (accessed Jan 23, 2013). http://www.worldcancerday.org/wcd-declaration.